Strong Early Promise For Takeda 'Off The Shelf' CAR-NK Therapy
Successful, Safe And Simple Alternative?
Executive Summary
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
You may also be interested in...
The Cancer Cell Therapy Showdown: CAR-Ts Versus CAR-NKs
Will CAR-NK cell therapies overshadow traditional CAR-T options for the treatment of some cancers? While preliminary data for CAR-NKs point to enhanced safety and solid tumor penetration, oncologists and executives discuss the pros and cons of these two approaches to cell therapy.
The Cancer Cell Therapy Showdown: CAR-Ts Versus CAR-NKs
Will CAR-NK cell therapies overshadow traditional CAR-T options for the treatment of some cancers? While preliminary data for CAR-NKs point to enhanced safety and solid tumor penetration, oncologists and executives discuss the pros and cons of these two approaches to cell therapy.
Takeda Buys Out Partner GammaDelta In Cell Therapy Push
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.